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Parkinson's DiseaseMutations in leucine-rich repeat kinase 2 (LRRK2), which are associated with autosomal dominant Parkinson's
disease, elicit progressive dendrite degeneration in neurons. We hypothesized that synaptic dysregulation con-
tributes to mutant LRRK2-induced dendritic injury. We performed in vitro whole-cell voltage clamp studies of
glutamatergic receptor agonist responses and glutamatergic synaptic activity in cultured rat cortical neurons ex-
pressing full-length wild-type and mutant forms of LRRK2. Expression of the pathogenic G2019S or R1441C
LRRK2mutants resulted in largerwhole-cell current responses to direct application of AMPA andNMDA receptor
agonists. In addition, mutant LRRK2-expressing neurons exhibited an increased frequency of spontaneous min-
iature excitatory postsynaptic currents (mEPSCs) in conjunction with increased excitatory synapse density as
assessed by immunoﬂuorescence for PSD95 and VGLUT1. Mutant LRRK2-expressing neurons showed enhanced
vulnerability to acute synaptic glutamate stress. Furthermore, treatment with the NMDA receptor antagonist
memantine signiﬁcantly protected against subsequent losses in dendrite length and branching complexity.
These data demonstrate an early association between mutant LRRK2 and increased excitatory synapse activity,
implicating an excitotoxic contribution to mutant LRRK2 induced dendrite degeneration.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disor-
der characterized by debilitating motor, and in many cases cognitive
deﬁcits. Efforts to understand the pathogenesis of PD have revealedK2-3HA, C-terminal 3×-hemag-
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mosome; CNQX, (6-cyano-7-
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rd error of the mean; DIV, days
niversity of Pittsburgh School of
.genetic factors that increase the risk of developing PD. Leucine-rich re-
peat kinase 2 (LRRK2)mutations underlie PARK8-linked familial parkin-
sonism [1,2]. This protein is believed to play important roles in both
familial and sporadic PD pathogenesis [3]. A deeper understanding of
the pathologic cascade that leads to neurodegeneration downstream
of mutant LRRK2 will likely render novel insights for the prevention
and treatment of PD.
Neurite injury is a conspicuous feature of mutant LRRK2-associated
neurodegeneration. Mutant LRRK2 expression in SH-SY5Y neuroblasto-
ma cell line cultures and inmouseprimary cortical neurons is associated
with neurite degeneration [4] or reduced dendrite outgrowth [5,6].
Mutant LRRK2 expression in neurons in vivo or in vitro results in neurite
injury that precedes cell death [7]. Functional neurotransmission abnor-
malities [8] and dystrophic neurite morphology have been reported in
transgenicmutant LRRK2mice [9,10].Whereas numerous effector path-
ways, including autophagy [7,10–13], mitochondrial pathology [14–16],
calcium toxicity [15], the ubiquitin proteasome [17], microtubule
1597E.D. Plowey et al. / Biochimica et Biophysica Acta 1842 (2014) 1596–1603stability [18], growth cone dynamics [6,19], Fas-associated protein with
death domain [20] and Rac1 [21], have been proposed, less is known
about the possible upstream impacts of LRRK2 on synaptic function
[22–25]. We hypothesize that synaptic dysregulation contributes to
dendrite injury in mutant LRRK2 expressing neurons.
To test our hypothesis, we determined whether alterations in excit-
atory synapses underlie neurite retraction in neurons expressing PD-
associated LRRK2 mutations. We found that mutant LRRK2-expressing
neurons show evidence of increased glutamatergic synapses and in-
creased vulnerability to synaptic glutamate stress, which occur well
before the onset of neurite degeneration. Furthermore, the NMDA re-
ceptor antagonist memantine partially protected neurons from mutant
LRRK2-induced dendrite degeneration. These ﬁndings suggest that mu-
tant LRRK2 is associated with enhanced glutamatergic synapses and
renders neurons more vulnerable to glutamate receptor toxicity.
2. Materials and methods
2.1. Neuronal cultures
Timed-pregnant female Sprague–Dawley rats (E16), obtained
from Hilltop Lab Animals, Inc. (Scottsdale, PA), were euthanized by
CO2 inhalation. This method of euthanasia is consistent with methods
suggested by the Panel on Euthanasia of the American Veterinary Med-
ical Association to minimize animal distress and was approved by the
University of Pittsburgh Institutional Animal Care and Use Committee
(IACUC). Embryos of either genderwere harvested in ice-cold Hanks so-
lution (Invitrogen). Cerebral cortices were dissected and dissociated via
trypsinization and gentle pipette trituration. Cell suspensionswere plat-
ed at a density of 100,000 cells/cm2 onto glass cover slips (Carolina Bio-
logical) or plastic culture dishes coated with poly-D-lysine (0.1 mg/ml;
Sigma) and laminin (5 μg/ml; Roche Diagnostics). Cultures were main-
tained at 37 °C with 5% ambient CO2 in Neurobasal medium
(Invitrogen) supplemented with B27 (Invitrogen) and 1% Glutamax-I
(Invitrogen). Media refreshments were performed every other day. In
some experiments, memantine, an NMDA receptor antagonist, was
added to the culture media following neuronal transfection to maintain
a concentration of 1 μM.
2.2. Molecular constructs and culture transfection
Full-length wild-type (WT) andmutant LRRK2 cDNAs (pathogen-
ic PDmutation G2019S or R1441C; kinase impaired K1906M)with C-
terminal triple-hemagglutinin tags (LRRK2-3HA) were expressed via
the pcDNA3.1 vector [11]. Neuronal cultures were co-transfected
with pRK7-eGFP and either empty pcDNA3.1 vector or mutant
LRRK2 cDNA constructs with 0.1% Lipofectamine 2000 reagent
(Invitrogen) on days in vitro (DIV) 12–15. A molar ratio of 1:2
(eGFP:LRRK2-3HA) was employed in electrophysiology experi-
ments, which yields 85% co-expression (Supplementary Fig. S1F-
G), and ratios of 1:2 and 1:9 were used in immunoﬂuorescence ex-
periments. A mouse anti-HA Tag IgG (Covance, Clone 16B12) was
used to conﬁrm LRRK2-3HA protein expression in neuroblastoma
cells viawestern blot (1:1000 primary antibody dilution) and in cul-
tured cortical neurons via immunocytochemistry (1:100 primary an-
tibody dilution). RT-PCR was performed on neuronal cultures with
primers spanning the junction of the C-terminus and the 3HA Tag
of the LRRK2 cDNAs (LRRK2-3HA primer sequences (403 base pair
product): LRRK2-7179-Forward: 5′-AAGGGAGGTAATGGTAAAAG
AAA-3′; LRRK2-3HA-Reverse: 5′-CCGCCCTCAACAGATGTTCG-3′;
eGFP primer sequences (402 base pair product): eGFP-Forward: 5′-
GAGCTGGACGGCGACGTAAACGG-3′; eGFP-Reverse: R: 5′-GACGTT
GTGGCTGTTGTAGTTG-3′). The transfection efﬁciency, determined
by GFP ﬂuorescence and HA Tag immunoﬂuorescence, was less
than 1% (40–75 neurons per cover slip). There was typically one
transfected neuron in a medium-power (100×) microscopic ﬁeld,allowing us to focus our analysis on the postsynaptic effects of mu-
tant LRRK2 expression in individual neurons in the context of non-
transfected presynaptic terminals from surrounding neurons.
2.3. Electrophysiological recordings
Coverslips containing rat primary cortical neuron cultures were
placed in a recording chamber containing Ringer solution (140 mM
NaCl, 2.8 mM KCl, 1 mM CaCl2, 10 mM HEPES, 10 mM glucose; pH 7.3)
with tetrodotoxin (2 μM) and strychnine (1 μM). Transfected cells ex-
pressing GFP were visualized via epiﬂuorescence microscopy. Whole-
cell voltage clamp recordings (Axopatch 200 Ampliﬁer) were obtained
with glass micropipettes (tip resistance 3–5 MΩ) ﬁlled with intracellu-
lar solution (130 mM CsCl, 10 mM HEPES, 10 mM EGTA for glutamate
receptor agonist responses and 118 mM Cs Methane Sulfonate,
12 mM CsCl, 10 mM HEPES, 10 mM EGTA for mEPSC recordings). The
mean± SEM series resistance was 16.1 ± 0.8 MΩ and was compensat-
ed at 80% in all experiments. Holding potentials were−55 mV for ago-
nist responses and−60 mV in mEPSC recordings (corrected for liquid
junction potentials of 5 and−10 mV, respectively). Cells were exposed
to ionotropic glutamate receptor agonists (100 μM AMPA or 10 μM
NMDA/10 μM glycine for 20 second periods) through a gravity-driven,
multi-barrel fast perfusion system [26]. NMDA receptor currents were
inhibited during applications of AMPA with 1 mM MgCl2. Data were
digitized (Digidata 1200) and recorded to a PC running pClamp 9.1 soft-
ware suite. Whole-cell current responses were quantiﬁed as the mean
steady state current during the ﬁnal 5 s of agonist applications. The
mEPSC mean amplitudes and frequencies were analyzed using the
event detection module of pClamp 9.1.
2.4. Synaptic protein immunocytochemistry
Cover slips were ﬁxed with 4% paraformaldehyde with 4% sucrose
followed by 100% methanol, permeabilized with 0.1% Triton-X and
blocked with Superblock Buffer (Thermo Scientiﬁc). Primary and sec-
ondary antibody concentrations employed were as follows: mouse
anti-PSD-95 IgG (1:200; Neuromab 75-028, UC Davis), mouse anti-
VGLUT1 IgG (1:200; Neuromab 75-066, UC Davis), rabbit anti-LRRK2
antibody (1:50; MJFF2 [c41-2], Abcam ab133474), Alexa Fluor 594-
conjugated donkey-anti-mouse and goat-anti-rabbit IgGs (1:1000;
Jackson ImmunoResearch Laboratories). Nuclei were counterstained
with DAPI (1:500; Invitrogen). Cover slips weremounted on glass slides
with gelvatol and imaged on an Olympus Fluoview 1000 confocal
microscope. Proximal dendrites were imaged from all consecutively
encountered transfected neurons for each LRRK2 construct per well
(25-80), using a 63× magniﬁcation, 1.40 NA apochromatic lens oil im-
mersion objective. Identical excitation and image acquisition parame-
ters were employed for all constructs. Images were analyzed for
synapse protein immunoﬂuorescence puncta with NIH ImageJ [27]. Im-
munoreactive puncta were identiﬁed on 50–250 μm GFP-positive den-
drite segments from each neuron using the NIH ImageJ intensity
threshold function and quantiﬁed with the Analyze Particles module
of NIH ImageJ with respect to puncta density (per micron of analyzed
dendrite length) and puncta area. The threshold intensity for each anti-
gen was set as themean plus 3 standard deviations of background den-
dritic cytoplasm signal sampled from 5 neurons. Identical background
measurements and intensity thresholds were employed in all transfec-
tion groups.
2.5. Synaptosome preparations and western blots
DIV15-17 rat cortical neurons were scraped and homogenized with
a 25G needle in HEPES-buffered sucrose [0.32 M sucrose, 5 mMHEPES,
pH 7.4] supplemented with protease inhibitor cocktail (Sigma, P8340).
Homogenized extracts were spun at 1000 g for 10min at 4 °C. Superna-
tant (S1) was centrifuged again at 1000 g for 10 min at 4 °C and saved
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the cytosolic (S2) fraction. The pellet was washed one time with 1 ml
HEPES-buffered sucrose and centrifuged again at 10,000 g for 15 min.
The washed pellet was either lysed for western blot analysis or lysed
rapidly with 1 ml ice-cold water with protease inhibitor, adjusted to
4mMHEPES and homogenized with a 25G needle. P2 lysates were cen-
trifuged at 25,000 g at 4 °C rendering crude synaptic vesicle fractions
(S3) and lysed synaptosomal membrane fractions (P3). Lysed synapto-
somal membranes were resuspended in HEPES-lysis buffer (50 mM
HEPES, pH 7.4, 2 mM EDTA, 0.5% Triton X, 1 mM NaF, 1 mM Na3VO4 a
protease inhibitor mixture) and centrifuged at 32,000 g for 20 min to
render solubilized synaptosomal membranes (S4) and PSD-1T fractions
(P4). For western blots, protein quantiﬁcation was performed via the
Bradfordmethod (Bio-rad, 500-0006) using a BioTek Epoch 96-wellmi-
croplate reader (BioTek, Winooski, VT, USA). Protein samples were
loaded into 4–15% Tris-Glycine gels (Bio-rad, 456-1085 and 456-1086)
and transferred onto PVDF membranes (Immobilon-P, Millipore,
IPVH00010). Immunoblotting was performed using the following pri-
mary antibodies: rabbit anti-LRRK2 antibody (1:1000; MJFF2 [c41-2],
Abcam ab133474), mouse anti-PSD95 MAGUK scaffold protein
(1:1000; clone K28/43, NeuroMab 73-028, UC Davis) and mouse anti-
GluN2B/NR2B glutamate receptor (1:1000; clone N59/36, NeuroMab
73-101, UC Davis). Blots were then labeled with secondary antibodies:
HRP-conjugated anti-mouse IgG (GE Healthcare, NXA-931) or HRP-
conjugated anti-rabbit IgG (GE Healthcare, NA934V). Immunoreactive
bands were detected by exposure of X-ray ﬁlm (Denville, E3018) fol-
lowing incubation of blots with ECL Prime chemiluminescence reagents
(GE Healthcare, RPN2236).
2.6. Excitotoxicity assay
At three days post-transfection, culture cover slips were transferred
to either physiologic Ringer solution or high K+ solution (90 mM KCl,
53 mM NaCl, 1 mM CaCl2, 10 mM HEPES, 10 mM glucose; pH 7.3) for
5 min. Cover slips were then returned to the incubator in their previous
conditioned growth medium for a period of 12 h. Cultures were then
ﬁxed, immunostained for cleaved caspase-3 (CC3) using rabbit poly-
clonal IgG (Cell Signaling #9661) diluted 1:1000 followed by Cy3-
conjugated anti-rabbit IgG (1:1000; Jackson ImmunoResearch) and
counterstained with DAPI (1:500 dilution; Invitrogen). Viable trans-
fected neurons (GFP-positive with neurite processes, CC3-negative,
vesicular nucleus) and apoptotic transfected neurons (GFP-positive,
CC3-positive, pyknotic nucleus) were quantiﬁed for each coverslip. Nu-
clear pyknosis always concurredwith positive CC3 immunostaining. Six
replicates were performed for each plasmid. Antagonists for AMPA
receptors (CNQX; 25 μM) and NMDA receptors (D-APV; 50 μM) were
included in a subset of cultures during and for 12 h following potassium
depolarization.
2.7. Neuronal morphology
GFP-expressing neurons were photographed using an Olympus
Provis epiﬂuorescencemicroscope. All transfected neurons on each cov-
erslip (range 50–75 neurons)were analyzed. Neurite length and branch
points were quantiﬁed using the NeuronJ extension of NIH ImageJ as
previously described [27,28].
2.8. Statistical analyses
Data are expressed as means ± SEM. Data from mutant and WT
LRRK2-transfected neurons in electrophysiology, immunoﬂuorescence
and excitotoxicity experiments were compared with data from vector
control-transfected neurons via Analyses of Variance (ANOVA) with
post-hoc Dunnett's Tests (SYSTAT Version 13.00.05). p b 0.05 was
deemed statistically signiﬁcant.3. Results
3.1. Mutant LRRK2-expressing neurons demonstrate increased current
responses to glutamate receptor agonists and increased spontaneous
excitatory synaptic activity
Weﬁrst recordedwhole-cell current responses to speciﬁc AMPA and
NMDA receptor agonists in DIV 17 cortical neurons co-transfected with
eGFP and eitherWT or one of several forms of mutant LRRK2-3HA three
days prior. Recordings were performed 3 days following transfection, a
timepoint that precedes signiﬁcant alterations in the dendritic lengths
of G2019S and R1441C LRRK2-expressing neurons (Supplementary
Fig. S1A, B). LRRK2-3HA construct expression was conﬁrmed in neuro-
nal cultures by RT-PCR (Supplementary Fig. S1C) and in B103 rat neuro-
blastoma cell cultures by western blot (Supplementary Fig. S1D).
Transfected neurons demonstrated MAP2 immunoreactivity (Supple-
mentary Fig. S1E). HA-Tag expression was detected in ~85% of GFP-
positive neurons transfected with WT, G2019S, R1441C, K1906M or
G2019S/K1906M LRRK2 (Supplementary Fig. S1F–G). Transfected neu-
rons were visualized by epiﬂuorescence microscopy and recorded in
whole-cell voltage clamp conﬁguration (Supplementary Fig. S1H).
Inward current responses to 100 μM AMPA were larger in G2019S
and R1441C LRRK2-expressing neurons compared to vector-transfected
neurons (Fig. 1A and B). WT LRRK2-transfected neurons showed a
trend towards an increased AMPA response, whereas kinase-impaired
K1906M LRRK2-transfected neurons showed no difference in the
AMPA response compared to control neurons. Current responses to
10 μM NMDA were also larger in G2019S and R1441C LRRK2-
transfected neurons (Fig. 1C and D), but were similar to vector control
responses in WT and K1906M LRRK2-transfected neurons. To deter-
mine if mutant LRRK2 impacts endogenous glutamatergic synaptic
activity, we performed voltage clamp recordings of mEPSCs in cortical
neurons expressing WT or mutant LRRK2 cDNAs. Mutant LRRK2-
expressing neurons showed increased frequencies of mEPSC events
compared to vector transfected neurons (Fig. 1E, F). There were no
differences in the mean mEPSC amplitudes among vector-, WT- and
mutant LRRK2-transfected neurons, providing no evidence for an alter-
ation in average synapse strength (Fig. 1G).3.2. Mutant LRRK2 expressing neurons show increased excitatory synaptic
protein immunoreactivity
We performed indirect immunoﬂuorescence labeling of excitatory
postsynaptic terminals with a PSD-95 antibody at 3 days following
transfection of neuronal cultures with LRRK2-3HA constructs. Trans-
fected neurons demonstrate punctate PSD-95 labeling colocalizing
with dendritic spines (Fig. 2A, B). LRRK2 itself was present in dendrites
and crude synaptosomal fractions, but was not enriched in dendritic
spines or PSD95-enriched fractions (Supplementary Fig. S2). How-
ever, G2019S and R1441C LRRK2-expressing neurons demonstrated
increased dendritic PSD-95 immunoreactivity compared to vector
transfected neurons (Fig. 2C). Analysis of relative PSD-95 puncta sizes
did not detect signiﬁcant differences among the different groups
(Vector: 100 ± 4%, n = 51; WT 101 ± 5%, n = 39; G2019S 112 ± 5%,
n = 48; R1441C 114 ± 5%, n = 42; K1906M 102 ± 5%, n = 38). To de-
termine whether the increased post-synaptic labeling corresponded
with an increase in excitatory synaptic markers, we performed immu-
nocytochemical labeling of the excitatory presynaptic protein VGLUT1,
which also demonstrated punctate reactivity abutting or colocalizing
with dendritic spines (Fig. 3A, B). A higher density of VGLUT1 labeling
was observed on dendrites in G2019S or R1441C LRRK2-transfected
neurons, but not K1906M LRRK2-transfected neurons (Fig. 3C). Ex-
pression of the double mutant G2019S/K1906M LRRK2 also had no ef-
fect on the density of VGLUT1 immunoreactive puncta (vector: 7.38 ±
0.60 puncta per 100 μm dendrite, n = 78; G2019S/K1906M LRRK2:
Fig. 1.Whole-cell current responses to glutamate receptor agonists andmEPSC activity are increased in LRRK2 transfected neurons. (A, B) Steady state inward current responses to 100 μM
AMPA at a holding potential of−55 mV were signiﬁcantly larger in G2019S- and R1441C-expressing neurons, but not in K1906M-expressing neurons (*p b 0.05 compared to vector-
transfected neurons, ANOVA: 4 df, F-Ratio: 2.552; nVector = 24; nWT= 18; nG2019S = 27; nR1441C = 18; n1906M= 14). WT LRRK2-transfected neurons showed a trend towards increased
AMPA responses. (C, D) Steady state inward current responses to 10 μM NMDA were signiﬁcantly larger in G2019S and R1441C LRRK2 overexpressing neurons (*p b 0.05 compared to
vector-transfected neurons, ANOVA: 4 df, F-Ratio: 3.996) but were unaltered with overexpression of WT or K1906M LRRK2. (E) Raw traces from mEPSC recordings (holding potential
−60 mV) showing increased mEPSC events per unit time in a R1441C LRRK2-transfected neuron (bottom) compared to the control vector-transfected neuron (top). (F) Composite
data demonstrate increased mean mEPSC frequencies in neurons overexpressing mutant G2019S LRRK2 (n= 10; p b 0.05) or R1441C LRRK2 (n = 10; p b 0.05) and a modest trend to-
wards increasedmEPSC frequency inWT LRRK2 (n=14) compared to vector control (n= 14) and K1906M LRRK2 (n=8; ANOVA: 4 df, F-Ratio: 2.654). (G) Therewere no differences in
the mean mEPSC amplitudes among treatment groups (ANOVA: 4 df, F-Ratio: 0.545).
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ment for LRRK2 kinase activity.3.3. Memantine partially protects against mutant LRRK2-induced
neurodegeneration
To determine if endogenous NMDA receptors contribute to mu-
tant LRRK2-induced neurite shortening, we treated G2019S LRRK2-
expressing neurons with the NMDA receptor antagonist memantine
(1 μM). Neuronal cultures were transfected on DIV 14 and then treated
with 1 μMmemantine continuously from 1 to 9 days following transfec-
tion (DIV 15–23; Fig. 4A). The blunted dendrite length associated with
9 days of 2019S LRRK2 expression was partially reversed by treatment
with 1 μMmemantine (Fig. 4B–C), and the number of dendrite branches
was completely restored withmemantine treatment (Fig. 4D). These re-
sults suggest that an NMDA receptor-dependentmechanism contributesto the progressive dendritic shortening and simpliﬁcation observed in
G2019S LRRK2-expressing neurons.
3.4. Mutant LRRK2 expression renders neurons more vulnerable to acute
synaptic glutamate stress
To determine if mutant LRRK2 increases neuronal sensitivity to
acute endogenous synaptic glutamate stress, we exposed transfect-
ed cortical neurons to a brief depolarizing stimulus (5 min of 90 mM
K+ Ringer) to evoke synaptic glutamate release. Following a post-
depolarization incubation of 12 h in conditioned growth media, cover
slips were ﬁxed and stained with an anti-cleaved caspase 3 antibody
and DAPI to reveal apoptotic transfected neurons (Fig. 4E). G2019S
and R1441C LRRK2-expressing neurons showed higher rates of apopto-
sis compared to control vector-transfected neurons (Fig. 4F). Blockade
of AMPA and NMDA receptors with CNQX and APV resulted in the pro-
tection of all neuronal culture treatment groups, demonstrating that the
Fig. 2. Pathogenic mutant LRRK2-transfected neurons show increased dendritic PSD-95
immunoreactivity. Medium (A) and high (B) power images of GFP/LRRK2 co-transfected
neurons immunostained for the glutamatergic postsynaptic marker PSD-95. Many PSD-
95 immunoreactive puncta are observed to colocalize with GFP positive dendrites
and spines. (C) Composite data showing increased dendritic PSD-95 immunoreactive
puncta on dendrites of neurons expressing G2019S LRRK2 (n = 26) or R1441C LRRK2
(n= 21), but not K1906M LRRK2 (n = 25) or WT LRRK2 (*p b 0.05 compared to control
vector dendrites (n = 26), ANOVA: 4 df, F-Ratio: 3.371).
Fig. 3. VGLUT1 immunoreactivity is increased around dendrites of mutant LRRK2-
expressing neurons. Medium (A) and high (B) power images of GFP/LRRK2 co-
transfected neurons immunostained for the glutamatergic presynaptic marker VGLUT1.
VGLUT1 immunoreactive puncta are observed to abut and colocalize with GFP positive
dendrites and spines. (C) Composite data showing increased dendritic VGLUT1 immuno-
reactivity around dendrites of G2019S LRRK2 (n = 36) and R1441C LRRK2 (n = 47)
transfected neurons but no signiﬁcant difference around WT LRRK2 or kinase impaired
K1906M LRRK2 transfected dendrites (n = 38) (*p b 0.001 compared to control vector
dendrites (n = 35), ANOVA: 4 df, F-Ratio: 10.002).
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dependent mechanisms (Fig. 4F).
4. Discussion
In this study, we investigated the impact of mutant LRRK2 expres-
sion on excitatory synapses in cultured rat cortical neurons prior to
the well-documented stage of progressive mutant LRRK2-induced
dendrite degeneration [7]. Neurons expressing mutant LRRK2 showed
increased whole-cell current responses to AMPA and NMDA recep-
tor agonists and increased mEPSC frequencies compared to vector-
transfected control neurons. We also found that cultured mutant
LRRK2-transfected neurons demonstrated increased densities of
VGLUT1 and PSD-95 immunoreactive puncta compared to control neu-
rons. Mutant LRRK2-expressing neurons demonstrated an increased
propensity for cell death induced by endogenous synaptic glutamate
stress. Furthermore, the NMDA receptor antagonist memantine con-
ferred signiﬁcant protection from mutant LRRK2-induced dendrite re-
traction, which begins 6 days after the observed electrophysiological
alterations. Our data suggest that excitatory synapse dysregulation con-
tributes to mutant LRRK2 induced neurodegeneration.
Increased mEPSC frequency could be due to either increased num-
bers of synapses or increased frequency of spontaneous presynapticsingle-vesicle fusion. While the transfection conditions in this study
allowed us to isolate the effects to postsynaptic expression of mutant
LRRK2, it is possible that a retrograde trans-synaptic effect could
promote spontaneous vesicle release in the untransfected presynaptic
terminals. Nevertheless, several lines of evidence support a role for
increased synapse density. Immunocytochemical labeling revealed in-
creases in both PSD-95 and VGLUT1 puncta densities along the den-
drites. The larger glutamatergic receptor agonist responses observed
inmutant LRRK2 transfected neurons are also consistentwith increased
densities of excitatory synapses. As mutant LRRK2 expression had no
effects on either mEPSC amplitude or PSD-95 puncta sizes, the data do
not support a modulatory effect for mutant LRRK2 on global synapse
strength. Rather, the data are most consistent with increased excitatory
synapse numbers as an early consequence of mutant LRRK2 expression.
Our study also implicates NMDA receptor activation as a contrib-
uting factor in the subsequent dendrite degeneration observed in
mutant LRRK2-expressing neurons. Memantine treatment restored
dendrite branching complexity and ameliorated the dendrite retrac-
tion phenotype observed in vehicle-treated G2019S LRRK2-
expressing neurons. NMDA receptorsmaymediate excitotoxic injury
via toxic Ca2+-mediated overactivation of neuronal enzymatic
Fig. 4. Neurons are partially protected from mutant LRRK2-induced neurodegeneration by the NMDA receptor antagonist memantine and show increased susceptibility to synaptic glu-
tamate stress. (A) Schematic of experimental design depicting continuous treatment of transfected neurons with 1 μMmemantine following transfection with vector or G2019S LRRK2.
(B) Representative neurons (arrowheads) 9 days following transfectionwith vector (left panel), G2019S LRRK2 (middle, showing severe blunting of the dendritic arborization) or G2019S
LRRK2 with 1 μMmemantine treatment (right). Compared to vector transfected neurons, G2019S LRRK2 transfected neurons demonstrated dendrite length attenuation (C; * p b 0.05,
ANOVA: 3 df, F-Ratio: 5.621) and dendritic branching complexity attenuation (D; * p b 0.05, ANOVA: 3 df, F-Ratio: 5.621), which were reversed by memantine treatment. (E, F) Cortical
cultures transfectedwith either vector ormutant LRRK2were subjected to 5min of depolarization with high K+ Ringer (90mM) in the presence or absence of AMPA and NMDA receptor
antagonists (25 μM CNQX and 50 μM D-APV). Following a 12-hour incubation period, cultures were ﬁxed and stained for CC3 (E). Signiﬁcantly larger proportions of pathogenic mutant
LRRK2 expressing neurons demonstrated apoptosis following synaptic glutamate exposure compared to vector transfected neurons (F) (*p b 0.05 compared to control ringer; #p b 0.05
compared to vector transfected neurons in high K+). No signiﬁcant apoptosis was seen in the presence of the glutamate receptor antagonists.
1601E.D. Plowey et al. / Biochimica et Biophysica Acta 1842 (2014) 1596–1603processes. While the potential toxicity of synaptic NMDA receptor
activation is controversial [29–31], extrasynaptic NMDA receptors
may also contribute to neurotoxicity by inhibiting protective signal-
ing cascades and activating toxic signaling pathways [32,33]. The
ability of memantine [34] to protect against mutant LRRK2-induced
dendrite degeneration is consistent with a potential role for
extrasynaptic NMDA receptors in mutant LRRK2 neurotoxicity.In addition, increased calcium ﬂux due to increased glutamatergic
excitability could impact several other pathological processes ascribed
tomutant LRRK2 expression.Mitochondrial perturbations have recently
been implicated in mutant LRRK2-associated toxicity. Mitochondrial
calcium overload in cortical neurons expressing either G2019S or
R1441C LRRK2 leads to enhanced dendritic mitophagy [15]. This loss
of mitochondrial density precedes dendritic retraction, and calcium
1602 E.D. Plowey et al. / Biochimica et Biophysica Acta 1842 (2014) 1596–1603chelators are able to prevent the changes in mitochondrial mem-
brane potential, mitophagy and dendrite shortening elicited by mutant
LRRK2. Mitophagy is dependent uponmitochondrial ﬁssion, and LRRK2
can interact with DLP1/DRP1 to promote mitochondrial fragmentation
in neuronal cells and neurons [14]. Interestingly, calcium dependent
phosphatases are involved in activating DLP1/DRP1 function [35], and
disrupted calcium homeostasis contributes to autophagy induction by
LRRK2 [36]. It is important to keep inmind, however, thatwhile autoph-
agy promotes dendrite retraction, this process could be initiated as a
compensatory response to eliminate excessive afferent glutamatergic
inputs.
Perturbation in cytoskeletal dynamics is another mechanism linked
to LRRK2-mediated neuritic pathology. LRRK2 has been reported to
interact with microtubules and to regulate actin remodeling [21,37].
Enhanced ezrin/radixin/moesin (ERM) protein phosphorylation and
blunting of early neurite outgrowth with G2019S LRRK2 expression
have been observed in immature (DIV 2) cultured neurons [6]. This in-
hibition of neurite outgrowthwith enhanced pERM-positive ﬁlopodia in
immature G2019S LRRK2 expressing neurons [6,19] may reﬂect com-
mencement of synaptogenesis in lieu of neurite ﬁeld expansion. In con-
trast, mutant LRRK2-induced dendrite shortening in pre-differentiated
SH-SY5Y cells and in more mature (DIV 14–23) neuron cultures in-
volves autophagy [11,13,15], and can be signiﬁcantly ameliorated by
an NMDA antagonist (Fig. 4).
The roles of LRRK2 kinase and GTPase domains in PD pathogenesis
are incompletely understood. The G2019S mutation employed in
these studies resides in the kinase domain activation loop and confers
an increase in kinase activity over WT LRRK2 [19,38–43]. We observed
increases in synaptic activity and protein immunoreactivity with
G2019S LRRK2 expression that were not seen in the presence of the ki-
nase impaired K1906Mmutation, suggesting a role for LRRK2 kinase ac-
tivity in the regulation of excitatory synapses. Similar effects were also
observed with the pathogenic R1441C LRRK2 mutation, which is char-
acterized by decreased GTPase activity [44,45] with inconsistent effects
on in vitro kinase activity (reviewed in [43]). While the relationship be-
tween GTPase and kinase activities remains to be fully deﬁned, pre-
served kinase activity is generally required for LRRK2-associated
toxicity [38,41].
Similar to several reports in the literature demonstrating inter-
mediate effects of WT LRRK2 overexpression [4,7,11,41], we found
that transfection with WT LRRK2 often elicited non-signiﬁcant trends.
These trends may be due to lesser increases in cellular LRRK2 kinase
activitywithWTLRRK2overexpression, or to the presence of physiolog-
ical feedback mechanisms that regulate WT LRRK2 but not mutant
forms of LRRK2. Transfected primary neuron cultures exhibited equiva-
lent LRRK2 mRNA expression among the WT, G2019S, R1441C and
K1906MLRRK2 constructs, and these constructs elicited equivalent pro-
tein expression levels in neuroblastoma cells (Supplementary Fig. 1).
Thus, the effects elicited by the disease-associated G2019S and
R1441C mutations are unlikely to be due simply to enhanced protein
expression or stability [46].
Interestingly, LRRK2 can interact with Parkin, an E3 ubiquitin ligase
that is mutated in PARK2-linked autosomal recessive juvenile par-
kinsonism [4]. When post-synaptically expressed, Parkin dampens
excitatory synaptic transmission by pruning excitatory synapses in cul-
tured hippocampal neurons [47]. Thus, either loss of Parkin function or
expression of dominant LRRK2mutations in the post-synaptic compart-
ment elicits increased numbers of excitatory synapses, contributing to
enhanced vulnerability to excitotoxicity. Additional putative LRRK2 reg-
ulatory targets relevant to excitatory synapse regulation include mRNA
translation [22] and mRNA degradation machineries [48], microtubules
[18,22,49], cell membrane-associated synaptic proteins [50] and Rho
GTPases [21].
Excitatory synapse dysregulation is an emerging theme in genetic
models of PD. Altered presynaptic vesicle recycling has been observed
in cultured cortical neurons with LRRK2 overexpression [24,51], orwith LRRK2 knockdown in presynaptic neurons of connected pairs
[23]. Lee et al. [22] described distinct LRRK2 mechanisms that impact
both pre- and postsynaptic functions in mutant Drosophila. Mutant
LRRK2 triggers selective dendritic mitophagy due to mitochondrial cal-
cium overload [15], and PKA protects against mutant LRRK2-mediated
dendrite degeneration through phosphorylation of the autophagy pro-
tein LC3 [13]. A recent work by Parisiadou et al. [52] reveals that
LRRK2 interacts with the regulatory subunit IIb of PKA to maintain the
PKA holoenzyme in dendritic shafts of striatal projection neurons, re-
ducing PKA in spines [52]. The R1441C LRRK2mutation impaired its in-
teraction with PKA, resulting in increased phospho-coﬁlin and
increased synaptic phospho-GluR1. These changes would be expected
to stabilize synapses, consistent with our observations. Interestingly,
our data implicate a role for LRRK2 kinase activity in excitatory synapse
dysregulation, whereas the G2019S mutation did not affect the LRRK2–
PKA interaction, suggesting that multiple downstream effector path-
waysmay contribute to the effects of LRRK2mutations on synaptic dys-
regulation. Our study is the ﬁrst to describe alterations in synaptic
activity following mutant LRRK2 overexpression in the postsynaptic
compartment of mammalian neurons. Furthermore, our data implicate
endogenous NMDA receptor activation as a contributing factor in mu-
tant LRRK2 induced dendrite degeneration.
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